Polymorphisms in GST enzymes can affect cancer risk and the effectiveness of chemotherapy.
A new PCR-based high-throughput genotyping assay has been developed that is cost-effective and reliable for large clinical trials.
The study shows a strong correlation between certain GST gene variants and an increased risk of specific cancers like acute lymphoblastic leukemia and osteosarcoma.